Compare ATRC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRC | AGIO |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 2005 | 2013 |
| Metric | ATRC | AGIO |
|---|---|---|
| Price | $58.15 | $33.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $51.17 | $38.88 |
| AVG Volume (30 Days) | ★ 907.1K | 664.8K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.74 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $201,630,000.00 | $43,011,000.00 |
| Revenue This Year | $15.27 | $76.75 |
| Revenue Next Year | $12.21 | $170.73 |
| P/E Ratio | $328.44 | ★ N/A |
| Revenue Growth | ★ 15.40 | N/A |
| 52 Week Low | $25.36 | $22.24 |
| 52 Week High | $59.59 | $46.00 |
| Indicator | ATRC | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 83.92 | 45.86 |
| Support Level | $26.95 | $32.54 |
| Resistance Level | N/A | $35.88 |
| Average True Range (ATR) | 2.04 | 1.25 |
| MACD | 0.34 | -0.01 |
| Stochastic Oscillator | 97.78 | 25.63 |
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.